Current Report Filing (8-k)

Date : 06/07/2019 @ 12:01PM
Source : Edgar (US Regulatory)
Stock : Aclaris Therapeutics, Inc. (ACRS)
Quote : 1.99  -0.11 (-5.24%) @ 11:00PM

Current Report Filing (8-k)

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8‑K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 6, 2019

 


 

Aclaris Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

Delaware

 

001-37581

 

46-0571712

(State or other jurisdiction of incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

 

640 Lee Road, Suite 200
Wayne, PA 19087

(Address of principal executive offices, including zip code)

 

(484) 324-7933

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

 

 

 

 

 

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.00001 par value

 

ACRS

 

The Nasdaq Stock Market, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)  or Rule 12b‑2  of the Securities Exchange Act of 1934 (§240.12b‑2  of this chapter).

Emerging growth company ☑

If an emerging growth company,  indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☑

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(b) On June 6, 2019, Stephen Tullman, the Chairman of the Board of Directors (the “ Board ”) of Aclaris Therapeutics, Inc. (the “ Company ”), resigned as Chairman and as a director of the Board effective June 7, 2019.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On June 6, 2019, the Company held its 2019 annual meeting of stockholders (the “ Annual Meeting ”). The stockholders considered two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 25, 2019.  Of the 41,269,643 shares outstanding as of the record date, 35,272,214 shares, or 85.46%, were present or represented by proxy at the Annual Meeting.  Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting. 

   

Proposal No. 1 :  Election of three nominees to serve as directors until the 2022 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:

   

 

 

 

 

 

 

Name

    

Votes For

    

Votes Withheld

 

Neal Walker

 

26,814,764

 

4,976,631

 

William Humphries

 

22,209,532

 

9,581,863

 

Andrew Schiff

 

26,766,604

 

5,024,791

 

 

 

 

Broker Non-Votes: 3,480,819 .  

   

All nominees were elected.

   

Proposal No. 2 :  Ratification of the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2019. The votes were cast as follows:

   

 

 

 

 

 

 

 

 

 

    

Votes For

    

Votes Against

    

Abstained

 

Ratification of appointment of PricewaterhouseCoopers LLP

 

35,198,683

 

69,673

 

3,858

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  

 

 

 

 

ACLARIS THERAPEUTICS, INC.

 

 

 

 

By:  

/s/ Frank Ruffo

Date:  June 7, 2019

 

Frank Ruffo
Chief Financial Officer

 

 

ACLARIS THERAPEUTICS, INC. (NASDAQ:ACRS)
Historical Stock Chart

1 Year : From Jul 2018 to Jul 2019

Click Here for more ACLARIS THERAPEUTICS, INC. Charts.

ACLARIS THERAPEUTICS, INC. (NASDAQ:ACRS)
Intraday Stock Chart

Today : Friday 19 July 2019

Click Here for more ACLARIS THERAPEUTICS, INC. Charts.

Latest ACRS Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.